Status:
COMPLETED
Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar
Lead Sponsor:
Hamad Medical Corporation
Conditions:
Coronavirus
COVID
Eligibility:
All Genders
18+ years
Brief Summary
Coronavirus Disease 2019 (COVID-19) is a disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. It was first isolated in Wuhan, China in December 2019 and then rapid...
Eligibility Criteria
Inclusion
- Adult patients ≥18 years of age
- Laboratory confirmed 2019-nCoV infection as determined by the PCR of the nasopharyngeal/oropharyngeal swab.
- Radiologically confirmed pneumonia (Based on the chest x-ray or CT scan imaging).
- Have received either Darunavir/Cobicistat or Lopinavir/Ritonavir as part of the treatment regimen for COVID-19 pneumonia
Exclusion
- No exclusion criteria will be applied
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04425382
Start Date
March 1 2020
End Date
September 30 2020
Last Update
August 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Corporation
Doha, Qatar